Section Arrow
LUNG.NASDAQ
- Pulmonx Corp
Quotes are at least 15-min delayed:2025/01/21 05:28 EST
Last
 6.26
-0.14 (-2.19%)
Day High 
6.5 
Prev. Close
6.4 
1-M High
7.27 
Volume 
140.22K 
Bid
2.53
Ask
9.95
Day Low
6.2 
Open
6.5 
1-M Low
5.72 
Market Cap 
252.72M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 6.66 
20-SMA 6.52 
50-SMA 6.57 
52-W High 14.835 
52-W Low 5.46 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.47/-1.16
Enterprise Value
288.92M
Balance Sheet
Book Value Per Share
2.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
68.68M
Operating Revenue Per Share
1.64
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QSIQuantum-Si2.24-0.3-11.81%-- 
SENSSenseonics Holdings0.8479-0.0271-3.10%-- 
BDMDBaird Medical Investment Holdings Ltd8.85+3.43+63.28%15.32PE
BMRABiomerica0.64-0.066-9.35%-- 
MDTMedtronic plc88.08+0.92+1.06%26.61PE
Quotes are at least 15-min delayed:2025/01/21 05:28 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.